MT-1303

DRUG6 trials

Sponsors

Tanabe Pharma Corporation, Bausch Health Americas, Inc.

Conditions

Crohn's DiseaseInflammatory Bowel DiseaseRelapsing-remitting Multiple SclerosisUlcerative Colitis

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

CompletedNCT01666327

Tanabe Pharma CorporationInflammatory Bowel Disease

Start: 2012-06-30End: 2014-07-31Updated: 2014-09-05

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

CompletedNCT02148185

Tanabe Pharma CorporationCrohn's Disease

Start: 2014-05-31End: 2014-06-30Updated: 2014-09-12

Mass Balance Study of MT-1303

CompletedNCT02293967

Tanabe Pharma CorporationRelapsing-remitting Multiple Sclerosis

Start: 2014-09-30End: 2014-12-31Updated: 2015-03-17

Phase 2

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

CompletedNCT02378688

Tanabe Pharma CorporationCrohn's Disease

Start: 2015-03-31End: 2016-10-31Updated: 2016-10-14

Extension Study of MT-1303 in Subjects With Crohn's Disease

CompletedNCT02389790

Tanabe Pharma CorporationCrohn's Disease

Start: 2015-08-31End: 2017-08-31Updated: 2017-09-05

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

CompletedNCT04857112

Bausch Health Americas, Inc.Ulcerative Colitis

Start: 2021-09-29End: 2024-11-08Updated: 2025-09-09

Related Papers

Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study

Xenobiotica2018-09-208 citations